[ Price : $8.95]
FDA tells gene therapy company uniQure that the agency may no longer view the companys Phase 1-2 data for its Huntingtons disease ...[ Price : $8.95]
FDA lifts a clinical hold against the Rein Therapeutics Phase 2 RENEW trial evaluating LTI-03 in patients with idiopathic pulmonar...[ Price : $8.95]
CBER director Vinay Prasad says FDA is preparing to introduce a new, accelerated pathway for approving custom gene-editing therapi...[ Price : $8.95]
FDA announces new actions aimed at protecting children from unapproved ingestible fluoride prescription drugs.[ Price : $8.95]
FDA grants interchangeability designations to Celltrions denosumab biosimilars, Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-...[ Price : $8.95]
FDA issues an updated safety communication confirming long-term post-approval data showing that the Hintermann Series H3 Total Ank...[ Price : $8.95]
Eli Lilly says its investigational weight-loss pill met most criteria for FDAs new national priority voucher program and could be ...[ Price : $8.95]
Johnson & Johnson files a supplemental BLA seeking to expand the use of its biologic therapy Stelara (ustekinumab) to treat childr...